PE20160885A1 - Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativos - Google Patents
Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativosInfo
- Publication number
- PE20160885A1 PE20160885A1 PE2016000650A PE2016000650A PE20160885A1 PE 20160885 A1 PE20160885 A1 PE 20160885A1 PE 2016000650 A PE2016000650 A PE 2016000650A PE 2016000650 A PE2016000650 A PE 2016000650A PE 20160885 A1 PE20160885 A1 PE 20160885A1
- Authority
- PE
- Peru
- Prior art keywords
- absent
- alkyl
- cycloalkyl
- halogen
- purine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a derivados de purina de formula (I) o sales farmaceuticamente aceptables de los mismos, en los cuales R1 es H, alquilo C1C6, alquenilo C2C6, cicloalquilo C3C6, heteroarilo de 4 a 6 miembros, entre otros; el anillo A es arilo C6C10 o heteroarilo de 5 a 12 miembros; R2 y R5 independientemente estan ausentes o son H, halogeno, CN, CHF2, CF3, alquilo C1C6, cicloalquilo C3C6, entre otros; R3 esta ausente o es H, halogeno, alquilo C1C6, alcoxi C1C6, cicloalquilo C3C6, entre otros; R4 esta ausente o es H, halogeno, alquilo C1C6 o cicloalquilo C3C6; Q esta ausente o es O, S o NH, entre otros; el anillo B esta ausente o es cicloalquilo C3C10, arilo C6C10 o heteroarilo de 5 a 12 miembros, entre otros; R6 y R8 independientemente estan ausentes o son H, halogeno, CN, OH, alquilo C1C3, alcoxi C1C3, entre otros; R7 es GC(O)CH=CH2, GSO2CH=CH2, GC(O)CH2Cl, GC(O)CH2CN, entre otros; G esta ausente cuando el punto de union a B es un atomo de N, o es NR18 cuando el punto de union a B es un atomo de C, donde R18 es H o alquilo C1C3; y m es 0, 1 o 2, con la condicion que m sea 2 cuando el anillo B este ausente. Tambien se refiere a composiciones farmaceuticas que comprenden dichos derivados de purina. Los derivados de purina de formula (I) son utiles para tratar el crecimiento celular anormal en mamiferos, como el cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907322P | 2013-11-21 | 2013-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160885A1 true PE20160885A1 (es) | 2016-09-11 |
Family
ID=52004011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000650A PE20160885A1 (es) | 2013-11-21 | 2014-11-10 | Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativos |
Country Status (39)
Country | Link |
---|---|
US (1) | US9290496B2 (es) |
EP (1) | EP3071570B1 (es) |
JP (2) | JP6166845B2 (es) |
KR (1) | KR101919672B1 (es) |
CN (1) | CN105916853B (es) |
AP (1) | AP2016009219A0 (es) |
AR (1) | AR098492A1 (es) |
AU (1) | AU2014351433B2 (es) |
CA (1) | CA2931034C (es) |
CL (1) | CL2016001151A1 (es) |
CR (1) | CR20160236A (es) |
CU (1) | CU24402B1 (es) |
CY (1) | CY1120478T1 (es) |
DK (1) | DK3071570T3 (es) |
DO (1) | DOP2016000115A (es) |
EA (1) | EA029842B1 (es) |
ES (1) | ES2681799T3 (es) |
GE (1) | GEP20186878B (es) |
GT (1) | GT201600091A (es) |
HR (1) | HRP20181036T1 (es) |
HU (1) | HUE039858T2 (es) |
IL (1) | IL245698B (es) |
LT (1) | LT3071570T (es) |
MA (1) | MA39043B1 (es) |
MD (1) | MD20160053A2 (es) |
MX (1) | MX2016006397A (es) |
MY (1) | MY184433A (es) |
NI (1) | NI201600072A (es) |
PE (1) | PE20160885A1 (es) |
PH (1) | PH12016500911A1 (es) |
PL (1) | PL3071570T3 (es) |
PT (1) | PT3071570T (es) |
RS (1) | RS57537B1 (es) |
SI (1) | SI3071570T1 (es) |
TN (1) | TN2016000188A1 (es) |
TW (1) | TWI538913B (es) |
UA (1) | UA115388C2 (es) |
UY (1) | UY35845A (es) |
WO (1) | WO2015075598A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
US9840517B2 (en) * | 2013-09-18 | 2017-12-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
CN107849036A (zh) * | 2015-05-12 | 2018-03-27 | 卡利拉制药公司 | 二环化合物 |
EP3541389A1 (en) * | 2016-11-16 | 2019-09-25 | Pfizer Inc | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
BR112019012682A2 (pt) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | moléculas quiméricas visando a proteólise de egfr e métodos associados de uso |
CA3056030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
IL269215B (en) | 2017-03-10 | 2022-09-01 | Pfizer | Disubstituted imidazole[4,5-c]quinoline derivatives |
EP3814354B1 (en) * | 2018-06-22 | 2023-11-08 | The Royal Institution for the Advancement of Learning / McGill University | Purine compounds and method for the treatment of cancer |
KR20200105631A (ko) * | 2019-02-28 | 2020-09-08 | 보로노이바이오 주식회사 | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 |
KR20230015944A (ko) * | 2020-05-20 | 2023-01-31 | 티와이케이 메디슨즈, 인코포레이티드 | Ret 키나아제 억제제로 사용되는 화합물 및 이의 용도 |
US20230131465A1 (en) | 2021-09-14 | 2023-04-27 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
JP3053222B2 (ja) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
US6790958B2 (en) | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
US6794390B2 (en) | 1996-08-02 | 2004-09-21 | Cv Therapeutics, Inc. | Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha |
SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
DE69817801T2 (de) | 1997-02-03 | 2004-03-11 | Pfizer Products Inc., Groton | Arylsulfonylhydroxamsäurederivate |
BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
EP0960098A1 (en) | 1997-02-11 | 1999-12-01 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
EP1003746A1 (en) | 1997-08-07 | 2000-05-31 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
CO5031249A1 (es) | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
MXPA02012870A (es) | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
KR100876069B1 (ko) | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
EP1377549A1 (en) | 2001-03-12 | 2004-01-07 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
WO2003009852A1 (en) | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CA2463563A1 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
WO2005016268A2 (en) | 2003-08-08 | 2005-02-24 | Mitochroma Research, Inc. | Alimentary compositions and methods for metabolic modulation |
US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
SG145748A1 (en) | 2003-08-15 | 2008-09-29 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
FR2876583B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
GB0502573D0 (en) | 2005-02-08 | 2005-03-16 | Topotarget As | Therapeutic compounds |
GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
EP2012791A4 (en) | 2006-02-07 | 2010-09-22 | Conforma Therapeutics Corp | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGUES AS INHIBITORS OF HSP90 |
CN101438288A (zh) | 2006-03-15 | 2009-05-20 | Csir公司 | 谷氨酰胺合成酶的磷酰基转移酶活性的调节 |
DK2076268T3 (da) | 2006-10-19 | 2013-04-22 | Genzyme Corp | Roscovitin til behandling af visse cystiske sygdomme |
WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
JP2010516774A (ja) | 2007-01-26 | 2010-05-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | マラリア原虫関連疾患を処置するためのキナーゼ阻害剤としてのプリン化合物および組成物 |
CA2683016A1 (en) * | 2007-03-07 | 2008-09-12 | Boehringer Ingelheim International Gmbh | 9h- purine derivatives and their use in the treatment of proliferative diseases |
AU2008287421A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Nitrogen containing bicyclic chemical entities for treating viral infections |
WO2009050199A1 (en) | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine al receptor ligands |
US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
EP2312945A4 (en) | 2008-08-13 | 2012-05-09 | Merck Sharp & Dohme | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER |
AR073397A1 (es) * | 2008-09-23 | 2010-11-03 | Palau Pharma Sa | Derivados de (r) -3- (n,n-dimetilamino) pirrolidina |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
EP2440559B1 (en) * | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
FR2945747A1 (fr) * | 2009-05-25 | 2010-11-26 | Centre Nat Rech Scient | Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9139592B2 (en) | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
CA2813571A1 (en) | 2010-06-22 | 2011-12-29 | University Of Central Florida Research Foundation, Inc. | Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3 |
MX2013004086A (es) * | 2010-10-14 | 2013-07-05 | Ariad Pharma Inc | Metodos para inhibir proliferacion celular en cancers accionados por egfr. |
US9238629B2 (en) * | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US8796255B2 (en) * | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
CN103501612B (zh) * | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
US8762299B1 (en) | 2011-06-27 | 2014-06-24 | Google Inc. | Customized predictive analytical model training |
CN103814030A (zh) | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
CN103159742B (zh) | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
JP6353788B2 (ja) | 2012-01-13 | 2018-07-04 | エイシア バイオサイエンシーズ インコーポレイテッド | 抗がん剤としての複素環式化合物およびその使用 |
MX2015012106A (es) | 2013-03-14 | 2016-01-12 | Pfizer | Combinacion de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cancer pulmonar de celulas no pequeñas. |
US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2014
- 2014-10-11 UA UAA201605505A patent/UA115388C2/uk unknown
- 2014-11-10 DK DK14806447.0T patent/DK3071570T3/en active
- 2014-11-10 RS RS20180909A patent/RS57537B1/sr unknown
- 2014-11-10 CN CN201480073530.7A patent/CN105916853B/zh active Active
- 2014-11-10 MA MA39043A patent/MA39043B1/fr unknown
- 2014-11-10 EP EP14806447.0A patent/EP3071570B1/en active Active
- 2014-11-10 PE PE2016000650A patent/PE20160885A1/es unknown
- 2014-11-10 PL PL14806447T patent/PL3071570T3/pl unknown
- 2014-11-10 TN TN2016000188A patent/TN2016000188A1/fr unknown
- 2014-11-10 AP AP2016009219A patent/AP2016009219A0/en unknown
- 2014-11-10 ES ES14806447.0T patent/ES2681799T3/es active Active
- 2014-11-10 HU HUE14806447A patent/HUE039858T2/hu unknown
- 2014-11-10 MY MYPI2016701796A patent/MY184433A/en unknown
- 2014-11-10 KR KR1020167016053A patent/KR101919672B1/ko active IP Right Grant
- 2014-11-10 EA EA201600337A patent/EA029842B1/ru not_active IP Right Cessation
- 2014-11-10 JP JP2016532623A patent/JP6166845B2/ja not_active Expired - Fee Related
- 2014-11-10 LT LTEP14806447.0T patent/LT3071570T/lt unknown
- 2014-11-10 CA CA2931034A patent/CA2931034C/en active Active
- 2014-11-10 PT PT148064470T patent/PT3071570T/pt unknown
- 2014-11-10 MX MX2016006397A patent/MX2016006397A/es unknown
- 2014-11-10 WO PCT/IB2014/065935 patent/WO2015075598A1/en active Application Filing
- 2014-11-10 SI SI201430806T patent/SI3071570T1/sl unknown
- 2014-11-10 CU CU2016000073A patent/CU24402B1/es unknown
- 2014-11-10 GE GEAP201414151A patent/GEP20186878B/en unknown
- 2014-11-10 AU AU2014351433A patent/AU2014351433B2/en not_active Ceased
- 2014-11-10 MD MDA20160053A patent/MD20160053A2/ro not_active Application Discontinuation
- 2014-11-19 UY UY0001035845A patent/UY35845A/es not_active Application Discontinuation
- 2014-11-20 TW TW103140297A patent/TWI538913B/zh not_active IP Right Cessation
- 2014-11-20 US US14/548,749 patent/US9290496B2/en active Active
- 2014-11-20 AR ARP140104368A patent/AR098492A1/es unknown
-
2016
- 2016-05-13 CL CL2016001151A patent/CL2016001151A1/es unknown
- 2016-05-17 PH PH12016500911A patent/PH12016500911A1/en unknown
- 2016-05-18 IL IL24569816A patent/IL245698B/en active IP Right Grant
- 2016-05-19 DO DO2016000115A patent/DOP2016000115A/es unknown
- 2016-05-20 GT GT201600091A patent/GT201600091A/es unknown
- 2016-05-20 NI NI201600072A patent/NI201600072A/es unknown
- 2016-05-20 CR CR20160236A patent/CR20160236A/es unknown
-
2017
- 2017-06-23 JP JP2017122759A patent/JP2017214390A/ja active Pending
-
2018
- 2018-07-05 HR HRP20181036TT patent/HRP20181036T1/hr unknown
- 2018-07-25 CY CY20181100779T patent/CY1120478T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160885A1 (es) | Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativos | |
CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
CY1124737T1 (el) | Ανταγωνιστες lpa | |
CY1121901T1 (el) | Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων | |
CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
NI201600007A (es) | Compuestos de n, 6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cáncer. | |
UY37900A (es) | Nuevos derivados de rapamicina | |
CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
CU24517B1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
NI201600040A (es) | Derivados de quinozolina sustituidos útiles como inhibidores de integrasa del vih | |
CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
PE20181145A1 (es) | Compuestos de piridina | |
PE20180483A1 (es) | Oxiesteroles y metodos de uso de los mismos | |
UA115354C2 (uk) | ПОХІДНІ ОКТАГІДРОПІРОЛО[3,4-c]ПІРОЛУ ТА ЇХ АНАЛОГИ ЯК ІНГІБІТОРИ АУТОТАКСИНУ | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
EA201791304A1 (ru) | Производные изохинолина для лечения вич |